Trivitron Healthcare will acquire 100% stake in Ani labsystem, a leader in the In Vitro Diagnostic.
Trivitron will acquire all four companies of Ani Labsystem namely Ani Biotech, Ani Labsystems, Biopoint and K3. The merger will be known as Labsystems Diagnostics OY- A Trivitron Group Company.
Ani Labsystem has a remarkable presence in Neonatal Screening and Cardiac Bio markers screening areas.
The acquisition will enable Trivitron enter into three fastest growing areas in In Vitro Diagnostic – Point of Care Diagnostics, Immuno Diagnostics and Molecular Diagnostics.
This will make Trivitron a global In Vitro Diagnostic company with capability of manufacturing variety of Diagnostics Kits covering all major areas of In Vitro Diagnostics Field.
In Chennai, Trivitron Healthcare has established South Asia’s first state-of-art medical technology manufacturing facility -The Trivitron Medical Technology Park and Trivitron’s innovation center at the IIT Madras.
The Trivitron Medical Technology Park enables cost effective manufacturing as per international standard in India.
“The factory based in India will enable Trivitron’s access to new infectious disease testing products for emerging markets and offer their customers new value oriented product lines in South Asia, South East Asia, Middle East and Africa,” commented G S K. Velu, Founder and Managing Director of Trivitron Healthcare.
“With a 15.8 million EURO foreign direct investment into Finland, the financial position of Ani Labsystems will be clearly strengthened. Ani Labsystems is the manufacturer of infectious disease laboratory diagnostics and neonatal screening since 30 years and Ani Biotech, the pioneering innovator and producer of home and point-of-care tests for cardiac, fertility, gastroenterology and infectious disease biomarkers for 25 years” says President Mika Saramaki.